|
|||||||
 |
Several studies have been conducted into to effectiveness of the newest class of drugs, tumor necrosis factor (TNF)-alpha blockers, in treating rheumatoid arthritis. But there have been no published studies comparing TNF-alpha blockers with the older class of drugs, known as disease-modifying anti-rheumatic drugs (DMARDS), such as Remicade (infliximab), Enbrel (etanercept), and Humira (adalimumab). Recently a team [...] A recent review of treatments for Psoriatic arthritis (PsA) found that the benefit of different therapies depended how widespread the disease was. Psoriatic arthritis is the second most common cause of joint inflammation. It involves the skin and joints, but may also affect fingers and toes, eyes and the spine. The effect on the skin is seen [...] The FDA has received 30 reports of cancer in children under the age of 18 who had been treated for JIA with anti-TNF drugs along with other medications, such as methotrexate, or similar immunosuppressant drugs. [...] Tumor necrosis factor (TNF) has been identified as having a key responsibility in many inflammatory diseases, including rheumatoid arthritis (RA). There has been substantial research into the early signaling pathways activated by TNF, but there is not much known about the delayed and chronic TNF responses. In addition, cells called macrophages (cells within the tissues that originate [...] Biogen Idec Inc. announced on October 9th that it was discontinuing development of its investigational rheumatoid arthritis (RA) drug baminercept after if failed to meet Phase II study endpoints. [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments